Multiple Sclerosis Relapses Following Cessation of Fingolimod

[1]  G. Marfia,et al.  What happens after fingolimod discontinuation? A multicentre real-life experience , 2021, Journal of Neurology.

[2]  C. Tornatore,et al.  Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations , 2019, Neurology and Therapy.

[3]  Y. Fragoso,et al.  Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod , 2019, Clinical Drug Investigation.

[4]  R. Grasso,et al.  Clinical activity after fingolimod cessation: disease reactivation or rebound? , 2018, European journal of neurology.

[5]  L. Kappos,et al.  Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis , 2018, Multiple sclerosis.

[6]  W. Takahashi,et al.  Neurological safety of fingolimod: An updated review , 2017, Clinical & experimental neuroimmunology.

[7]  T. Ziemssen,et al.  Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. , 2017, Autoimmunity reviews.

[8]  M. Tsolaki,et al.  Data quality evaluation for observational multiple sclerosis registries , 2017, Multiple sclerosis.

[9]  P. Soelberg Sørensen,et al.  A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod , 2017, Multiple sclerosis.

[10]  D. Centonze,et al.  Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis , 2017, Journal of Neurology.

[11]  R. Bhatia,et al.  Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study , 2016, Neurology.

[12]  P. Vermersch,et al.  Comparative efficacy of fingolimod vs natalizumab , 2016, Neurology.

[13]  B. Khatri.  Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence , 2016, Therapeutic advances in neurological disorders.

[14]  J. Bowen,et al.  The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis , 2015, CNS Drugs.

[15]  G. Salanti,et al.  Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. , 2015, The Cochrane database of systematic reviews.

[16]  Jeffrey A. Cohen,et al.  Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis , 2015, CNS Drugs.

[17]  R. Gold,et al.  Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment , 2015, Therapeutic advances in neurological disorders.

[18]  Niklas Luetzen,et al.  Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation , 2015, Journal of Neuroimmunology.

[19]  J. Lechner-Scott,et al.  Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. , 2015, JAMA neurology.

[20]  J. Lechner-Scott,et al.  Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis , 2015, Annals of neurology.

[21]  J. Lechner-Scott,et al.  Fingolimod after natalizumab and the risk of short-term relapse , 2014, Neurology.

[22]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[23]  L. Kappos,et al.  MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.